Multimodality imaging of hypoxia in preclinical settings

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 3, 2010, Pages 259-280

  Mason, R P ^a   Zhao, D ^a   Pacheco Torres, J ^a   Cui, W ^a   Kodibagkar, V D ^a   Gulaka, P K ^a   Hao, G ^a   Thorpe, P ^a   Hahn, E W ^a   Peschke, P ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cell hypoxia; Hexafluorobenzene; Magnetic resonance imaging; Neoplasms; Oxygen

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; FLUORINE; LUCIFERASE; MISONIDAZOLE; NITROXIDE; PENTETIC ACID; PHOSPHATIDYLSERINE; PIMONIDAZOLE;

CARCINOMA IN SITU; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TARGETING; HUMAN; HYPOXIA; IMAGING; MAGNETISM; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIMETRY; OXYGEN TENSION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; RADIOBIOLOGY; REVIEW; RODENT; STATISTICAL SIGNIFICANCE; TUMOR;

ANIMALS; ANOXIA; MOLECULAR IMAGING; NEOPLASMS, EXPERIMENTAL; OXIMETRY; TUMOR MICROENVIRONMENT;

EID: 77958537523     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. Gray L, Conger A, Ebert M, Hornsey S, Scott O. The concentration of oxygen dissolved in tissues at time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48.
2. Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW et al. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat. Biol 2006;82:699-757.
3. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10-21.
4. Moulder J, Rockwell S. Hypoxic fractions of solid tumors, experimental technique, methods of analysis and survey of existing data. Int J Radiat Oncol Biol Phys 1984;10: 695-712.
5. Dewhirst MW, Klitzman B, Braun RD, Brizel DM, Haroon ZA, Secomb TW. Review of methods used to study oxygen transport at the microcirculatory level. Int J Cancer 2000;90:237-55.
6. Zhao D, Jiang L, Mason RP. Measuring changes in tumor oxygenation. Methods Enzymol 2004;386:378-418.
7. Swartz HM, Dunn JF. Measurements of oxygen in tissues: overview and perspectives on methods. In: Dunn JF, Swartz HM, editors. Oxygen transport to tissue XXIV. Vol. 530. New York, NY: Kluwer Academic; 2003. p. 1-12.
8. Foo SS, Abbott DF, Lawrentschuk N, Scott AM. Functional imaging of intratumoral hypoxia. Molecular Imaging Biol 2004;6:291-305.
9. 19F magnetic resonance. In: Tressaud A, Haufe G, editors. Fluorine and Health. New York, NY: Elsevier B.V.; 2008. p. 198-276.
10. Knowles HJ, Harris AL. Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis. Breast Cancer Res 2001;3:318-22.
11. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
12. Cairns RA, Kalliomaki T, Hill RP. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res 2001;61:8903-8.
13. Jain RK, Schlenger K, Höckel M, Yuan F. Quantitative angiogenesis assays: Progress and problem. Nature Med 1997;3:1203-8.
14. Ran S, Thorpe PE. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 2002;54:1479-84.
15. Jennewein M, Lewis M, Zhao D, Tsyganov T, Slavine N, He J et al. Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. Clin Cancer Res 2008;14:1377-85.
16. Rademakers SE, Span PN, Kaanders JHAM, Sweep FCGJ, van der Kogel AJ, Bussink J. Molecular aspects of tumour hypoxia. Molecular Oncology 2008;2:41-53.
17. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49:129S-48S.
18. Fomicheva EV, Turner II, Edwards TG, Hoff J, Arden E, D'Alecy LG et al. Double oxygen-sensing vector system for robust hypoxia/ischemia-regulated gene induction in cardiac muscle in vitro and in vivo. Molecular Therapy 2008;16:1594-601.
19. Penet M-F, Pathak AP, Raman V, Ballesteros P, Artemov D, Bhujwalla ZM. Noninvasive multiparametric imaging of metastasis-permissive microenvironments in a human prostate cancer xenograft. Cancer Res 2009;69:8822-9.
20. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 1997;147:541-50.
21. Fowler JF, Tome WA, Fenwick JD, Mehta MP. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 2004;60:1241-56.
22. Timmerman RD, Paulus R, Galvin J, Michalski J, Straube W, Bradley J et al. Stereotactic body radiation therapy for medically inoperable early-stage lung cancer patients: analysis of RTOG 0236. Int J Radiat Oncol Biol Phys 2009;75:S3-S3.
23. Flynn RT, Bowen SR, Bentzen SM, Mackie TR, Jeraj R. Intensity-modulated X-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys Med Biol 2008;53:4153-67.
24. Yang Y, Xing L. Towards biologically conformai radiation therapy (BCRT): Selective IMRT dose escalation under the guidance of spatial biology distribution. Medical Physics 2005;32:1473-84.
25. Malinen E, Sovik A, Hristov D, Bruland OS, Olsen DR. Adapting radiotherapy to hypoxic tumours. Phys Med Biol 2006;51:4903-21.
26. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: A planning study. Int J Radiat Oncol Biol Phys 2007;68:291-300
27. Albertella MR, Loadman PM, Jones PH, Phillips RM, Rarnpling R, Burnet N et al. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: Results of a phase I study. Clinical Cancer Research 2008;14:1096-104.
28. Duan J-X, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 2008;51:2412-20.
29. Kaanders JHAM, Wijffels KIEM, Marres HAM, Ljungkvist ASE, Pop LAM, van den Hoogen FJA et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-74.
30. Raleigh JA, Chou SC, Arteel GE, Horsman M. Comparison among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 1999;151:580-9.
31. Dolbier WR Jr, Li AR, Koch CJ, Shiue CY, Kachur AV. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isotop 2001;54:73-80.
32. Evans SM, Hahn S, Pook DR, Jenkins WT, Chalian AA, Zhang P et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 2000;60:2018-24.
33. Ljungkvist ASE, Bussink J, Rijken PFJW, Raleigh JA, Denekamp J, Van Der Kogel AJ. Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys 2000;48:1529-38.
34. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govinda R, Laforest R et al. In vivo assessment of tumor hypoxia in lung cancer with (60)Cu-ATSM. Eur J Nucl Med Molec Imaging 2003;30:844-50.
35. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229-37.
36. Koch CJ. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2 -nitroimidazole EF5. Methods Enzymol 2002;352:3-31.
37. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003;55:1233-8.
38. Robinson SP, Griffiths JR. Current issues in the utility of F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia. Phil Trans R Soc London B Biol Sci 2004;359:987-96.
39. 19F magnetic resonance spectroscopy in vim. Int J Radiat Oncol Biol Phys 1989;16:925-9.
40. Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med 2001;31:321-9.
41. Fang SW, Hong MT, Zhang H. Positron emission tomography imaging of tumor hypoxia. Current Medical Imaging Reviews 2010;6:8-16.
42. Mees G, Dierckx R, Vangestel C, Van de Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009;36:1674-86.
43. Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D et al. Imaging of tumor hypoxia with [I-124] IAZA in comparison with [F-18] FMISO and [F-181FAZA - first small animal PET results. J Pharm Pharm Sci 2007;10:203-11.
44. Riedl C, Brader P, Zanzonico P, Reid V, Woo Y, Wen B et al. Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort. Eur J Nucl Med Mol Imaging 2008;35:39-46.
45. McQuade P, Rowland DJ, Lewis JS, Welch MJ. Positron-emitting isotopes produced on biomedical cyclotrons. Curr Med Chem 2005;12:807-18.
46. Liu J, Hajibeigi A, Ren G, Lin M, Siyambalapitiyage W, Liu ZS et al. Retention of the radiotracers Cu-64-ATSM and Cu-64-PTSM in human and murine tumors is influenced by MDR1 protein expression. J Nucl Med 2009;50:1332-9.
47. O'Donoghue JA, Zanzonico P, Pugachev A, Wen BX, Smith-Jones P et al. Assessment of regional tumor hypoxia using F-18-fluoromisonidazole and Cu-64(H)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po-2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005;61:1493-502.
48. Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 2008;49:1177-82.
49. Jennewein M, Hermanne A, Mason RP, Thorpe PE, Rösch F. A new method for the labelling of proteins with radioactive arsenic isotopes. Nuclear instruments and methods in physics research section A. Nucl Instrum Methods Phys Res A 2006;569:512-7.
50. Cherk MH, Foo SS, Poon AMT, Knight SR, Murone C, Papenfuss AT et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by F-18-fluoromisonidazole and F-18-FDG PET. J Nucl Med 2006;47:1921-6.
51. Swartz HM. Measuring real levels of oxygen in vivo: opportunities and challenges. Biochem Soc Trans 2002;30:248-52.
52. Cater D, Silver I. Quantitative measurements of oxygen tension in normal tissues and in the tumors of patients before and after radiotherapy. Acta Radiol 1960;53:233-56.
53. Fyles A, Milosevic M, Pintilie M, Syed A, Levin W, Manchul L et al. Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiother Oncol 2006;80:132-7.
54. Brizel DM, Sibly GS, Prosmitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int Radiat Oncol Biol Phys 1997;38:285-9.
55. Höckel M, Schlenger K, Aral B, Mitze M, Schäffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of me uterine cervix. Cancer Res 1996;56:4509-15.
56. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;20:680-7.
57. Fyles AW, Milosevic M, Wong R, Kavanagh M-C, Pintile M, Sun A et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-56.
58. Yeh KA, Biade S, Lanciano RM, Brown DQ, Fenning MC, Babb JS et al. Polarographic needle electrode measurements of oxygen in rat prostate carcinomas: accuracy and reproducibility. Int J Radiat Oncol Biol Phys 1995;33:111-8.
59. Aquino-Parsons C, Green A, Minchinton A. I. Oxygen tension in primary gynaecological tumours: the influence of carbon dioxide concentration. Radiother Oncol 2000;57:45-51.
60. Partridge SE, Aquino-Parsons C, Luo C, Green A, Olive PL. A pilot study comparing intratumoral oxygenation using the comet assay following 2.5% and 5% carbogen and 100% oxygen. Int J Radiat Oncol Biol Phys 2001;49:575-80.
61. Gu Y, Bourke V, Kim JG, Constantinescu A, Mason RP, Liu H. Dynamic response of breast tumor oxygenation to hyperoxic respiratory challenge monitored with three oxygen-sensitive parameters. Applied Optics 2003;42:1-8.
62. Zhao D, Constantinescu A, Hahn EW, Mason RP. Tumor oxygen dynamics with respect to growth and respiratory challenge: investigation of the Dunning prostate R3327-HI tumor. Radiat Res 2001;156:510-20.
63. Jordan BF, Beghein N, Aubry M, Gregoire V, Gallez B. Potentiation of radiation-induced regrowth delay by isosorbide dinitrate in FSaII murine tumors. Int J Cancer 2003;103:138-41.
64. Kuppusamy P, Afeworki R, Shankar RA, Coffin D, Krishna MC, Hahn SM et al. In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model. Cancer Res 1998;58:1562-8.
65. Elas M, Williams BB, Parasca A, Mailer C, Pelizzari CA, Lewis MA et al. Quantitative tumor oxymetric images from 4D electron paramagnetic resonance imaging (EPRI): methodology and comparison with blood oxygen level-dependent (BOLD) MRI. Magn Reson Med 2003;49:682-91.
66. O'Hara JA, Goda F, Demidenko E, Swartz H. M. Effect on regrowth delay in a murine tumor of scheduling split-dose irradiation based on direct pO measurements by electron paramagnetic resonance oximetry. Radiat Res 1998;150:549-56.
67. Gallez B, Jordan BF, Baudelet C, Misson PD. Pharmacological modifications of the partial pressure of oxygen in murine tumors: evaluation using in vivo EPR oximetry. Magn Reson Med 1999;42:627-30.
68. Liu H, Song Y, Worden KL, Jiang X, Constantinescu A, Mason RP. Noninvasive investigation of blood oxygenation dynamics of tumors by near-infrared spectroscopy. Appl Optics 2000;39:5231-43.
69. Gallez B, Baudelet C, Jordan BF. Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications. NMR Biomed 2004;17:240-62.
70. Kodibagkar VD, Wang X, Mason RP. Physical principles of quantitative nuclear magnetic resonance oximetry. Front Biosci 2008;13:1371-84.
71. Harris AL. Hypoxia a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
72. Morse DL, Gillies RJ. Molecular imaging and targeted therapies. Biochemical Pharmacology [In press].
73. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of trans-tasman radiation oncology group study 98.02. J Clin Oncol 2006;24:2098-104.
74. 19F NMR of perfluorocarbon. Art Cells Blood Sub Immob Biotech 1994;22:1141-53.
75. 19F spectroscopy of perfluorocarbon. Magn Reson Med 1993;29:296-302.
76. Mason RP, Antich PP, Babcock EE, Constantinescu A, Peschke P, Hahn EW. Non-invasive determination of tumor oxygen tension and local variation with growth. Int J Radiat Oncol Biol Phys 1994;29:95-103.
77. 19F Inversion-recovery Echo-planar imaging of Perfluoro-15-crown-5- ether. Magn Reson Med 1994;32:88-97.
78. 19F echo planar NMR imaging of sequestered perfluorocarbon. JMRI 1994;4:595-602.
79. 19F MR EPI and electrodes. In: Dunn JF, Swartz HM, editors. Oxygen transport to tissue XXIV. Vol. 530. New York, NY: Kluwer; 2003. p. 19-28.
80. 2 mapping. J Biomed Optics 2003;8:53-62.
81. Zhao D, Ran S, Constantinescu A, Hahn EW, Mason RP. Tumor oxygen dynamics: correlation of in vivo MRI with histological findings. Neoplasia 2003,5:308-18.
82. 19F magnetic resonance imaging in rats. Phys Med Biol 2006;51:45-60.
83. 19F NMR spectroscopy of hexafluorobenzene. Int J Radiat Oncol Biol Phys 1998;40:101-71.
84. Zhao D, Constantinescu C, Hahn EW, Mason RP. Differential oxygen dynamics in two diverse Dunning prostate R3327 rat tumor sublines (MAT-Lu and HI) with respect to growth and respiratory challenge. Int J Radiat Oncol Biol Phys 2002;53:744-56.
85. Zhao D, Constantinescu A, Chang C-H, Hahn EW, Mason RP. Correlation of tumor oxygen dynamics with radiation response of the Dunning prostate R3327-HI tumor. Radiat Res 2003;159:621-31.
86. Bourke VA, Zhao D, Gilio J, Chang C-H, Jiang L, Hahn EW Mason RP. Correlation of radiation response with tumor oxygenation in the dunning prostate R3327-AT1 tumor. Int J Radiat Oncol Biol Phys 2007;67:1179-86.
87. Xia M, Liu H, Ren Y, Mason R, Levine B. Simultaneous monitoring of tumor vascular and tissue oxygen tension under hyperbaric oxygen exposure. Proceedings of the Biomedical Optics Topical Meeting; Fort Lauderdale, FL, USA; 2006.
88. Zhao D, Constantinescu A, Jiang L, Hahn EW, Mason RP. Prognostic radiology: quantitative assessment of tumor oxygen dynamics by MRI. Am J Clin Oncol 2001;24:462-6.
89. Zhao D, Jiang L, Hahn EW, Mason RP. Tumor physiological response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 2005;62:872-80.
90. 1H NMR approach to quantitative tissue oximetry using hexamethyldisiloxane. Magn Reson Med 2006;55:743-8.
91. Kodibagkar VD, Wang X, Pacheco-Torres J, Gulaka P, Mason RP. Proton imaging of siloxanes to map tissue oxygenation levels (PISTOL): a tool for quantitative tissue oximetry. NMR Biomed 2008;21:899-907.
92. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001;14:497-506.
93. Xu F, Ge YL, Lu HZ. Noninvasive quantification of whole-brain cerebral metabolic rate of oxygen (CMRO ) by MRI. Magn Reson Med 2009;62:141-8.
94. Wright GA, Hu BS, Macovski A. Estimating oxygen saturation of blood in vivo with MR imaging at 1.5 T. JMRI 1991;1:275-83.
95. He X, Yablonskiy DA. Quantitative BOLD: mapping of human cerebral deoxygenated blood volume and oxygen extraction fraction: default state. Magn Reson Med 2007;57:115-26.
96. Robinson SP, Rijken PF, Howe FA, McSheehy PM, van der Sanden BP, Heerschap A et al. Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imaging 2003;17:445-54.
97. Griffiths JR, Taylor NJ, Howe FA, Saunders MI, Robinson SP, Hoskins PJ et al. The response of human tumors to carbogen breathing monitored by gradient-recalled echo MRI. Int J Radiat Oncol Biol Phys 1997;39:697-701.
98. Al-Hallaq HA, River JN, Zamora M, Oikawa H, Karczmar GS. Correlation of magnetic resonance and oxygen microelectrode measurements of carbogen-induced changes in tumor oxygenation. Int J Radiat Oncol Biol Phys 1998;41:151-9.
99. Dunn JF, O'Hara JA, Zaim-Wadghiri Y, Lei H, Meyerand ME, Grinberg OY et al. Changes in oxygenation of intracranial tumors with carbogen: a BOLD MRI and EPR oximetry study. JMRI 2002;16:511-21.
100. 19F MRI to investigate tumor oxygenation. Magn Reson Med 2009;62:357-64.
101. Baudelet C, Gallez B. Current issues in the utility of blood oxygen level dependent MRI for the assessment of modulations in tumor oxygenation. Curr Med Imaging Rev 2005;1:229-43.
102. 2) inside tumors? Magn Reson Med 2002;48:980-6.
103. Taylor NJ, Baddeley H, Goodchild KA, Powell ME, Thoumine M, Culver LA et al. BOLD MRI of human tumor oxygenation during carbogen breathing. JMRI 2001;14:156-63.
104. Padhani A, Krohn K, Lewis J, Alber M. Imaging oxygenation of human tumours. Europ Radiol 2007;17:861-72.
105. Hoskin PJ, Carnell DM, Taylor NJ, Smith RE, Stirling JJ, Daley FM et al. Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry initial observations. Int J Radiat Oncol Biol Phys 2007;68:1065-71.
106. Rodrigues LM, Howe FA, Griffiths JR, Robinson SP. Tumor R-2 * is a prognostic indicator of acute radiotherapeutic response in rodent tumors. J Magn Reson Imaging 2004;19:482-8.
107. Gullino PM, Granthan FH, Courtney AH. Utilization of oxygen by transplanted tumors in vivo. Cancer Res 1967;27:1020-9.
108. Vaupel P. Atemgaswechsel und Glucosestoffwechsel von Implantationstumoren (DS-Carcinosarkom) in vivo. Vol. I. Mainz: Akademie der Wissenschaften und der Literatur; 1974. p. 5-138.
109. Matsumoto K, Bernardo M, Subramanian S, Choyke P, Mitchell JB, Krishna M et al. MR assessment of changes of tumor in response to hyperbaric oxygen treatment. Magn Reson Med 2006;56:240-6.
110. Edelman RR, Hatabu H, Tadamura E, Li W, Prasad PV. Noninvasive assessment of regional ventilation in the human lung using oxygen-enhanced magnetic resonance imaging. Nature Medicine 1996;2:1236-9.
111. O'Connor JPB, Jackson A, Buonaccorsi GA, Buckley DL, Roberts C, Watson Y, Cheung S et al. Organ-specific effects of oxygen and carbogen gas inhalation on tissue longitudinal relaxation times. Magn Reson Med 2007;58:490-6.
112. O'Connor JPB, Naish JH, Jackson A, Waterton JC, Watson Y, Cheung S et al. Comparison of normal tissue R-1 and R-2* modulation by oxygen and carbogen. Magn Reson Med 2009;61:75-83.
113. Jones RA, Ries M, Moonen CTW, Grenier N. Imaging the changes in renal T-1 induced by the inhalation of pure oxygen: A feasibility study. Magn Reson Med 2002;47:728-35.
114. Tadamura E, Hatabu H, Li W, Prasad PV, Edelman RR. Effect of oxygen inhalation on relaxation times in various tissues. J Magn Reson Imaging 1997;7:220-5.
115. Berkowitz BA, McDonald C, Ito Y, Tofts PS, Latif Z, Gross J. Measuring the human retinal oxygenation response to a hyperoxic challenge using MRI: eliminating blinking artifacts and demonstrating proof of concept. Magn Reson Med 2001;46:412-6.
116. Lewa CJ, Majewska. Temperature relationships of proton spin-lattice relaxation time T1 in biological tissues. Bull Cancer 1980;67:35.
117. 19F magnetic resonance imaging: simultaneous comparison with fluorescence quenching. Magn Reson Med 2009;61:634-8.
118. 19F MRI. Proceedings of 16th ISMRM; Toronto, ON, Canada; 2008. p. 197.
119. 19F MRI in a rat model. Proceedings of ISMRM; Honolulu, HI, USA; 2009.
120. Diepart C, Karroum O, Magat J, Feron O, Jordan B, Gallez B. MR characterization of the tumor microenvironment after arsenic trioxide treatment: evidence for an effect on oxygen consumption that radiosensitizes solid tumors. Proceedings of Joint ISMRM-ESMRMB; Stockholm, Sweden; 2010.
121. Jordan BF, Peeterbroeck J, Karroum O, Diepart C, Magat J, Gregoire V et al. Captopril and S-nitrosocaptopril as potent radiosensitizers: Comparative MR study and underlying mechanisms. Proceedings of the Joint ISMRM-ESMRMB; Stockholm, Sweden; 2010.
122. 19F MRI in a rat model. Proceedings of the ISMRM; Stockholm, Sweden; 2010.
123. 2 measurements of perfluorocarbon labeled 9L glioma cells. Proceedings of 16th Intl Soc Mag Reson Med; Toronto, ON, Canada; 2008. p. 800.
124. Wickline SA, Mason RP, Caruthers SD, Chen J, Winter PM, Hughes MS et al. Fluorocarbon agents for quantitative multimodal molecular imaging and targeted therapeutics. In: Weissleder R, Gambhir SS, Ross BD, Rehemtulla A, editors. Hamilton, ON, Canada: BC Decker Inc.; 2010.
125. Procissi D, Claus F, Burgman P, Koziorowski J, Chapman JD, Thakur SB et al. In vivo F-19 magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clinical Cancer Res 2007;13:3738-47.
126. Kodibagkar VD, Gulaka PK, Rojas-Quinjano F, Kovacs ZP, Sherry AD, Mason RP. In vitro and in vivo evaluation of GdDO3NI as a hypoxia targeting MRI T1 contrast agent". Proceedings of ISMRM; Stockholm, Sweden; 2010.
127. Jiang L, Zhao D, Constantinescu A, Mason RP. Comparison of BOLD contrast and Gd-DTPA dynamic contrast enhanced imaging in rat prostate tumor. Magn Reson Med 2004;51.953-60.
128. O'Connor JPB, Naish JH, Parker GJM, Waterton JC, Watson Y, Jayson GC et al. Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys 2009;75:1209-15.
129. Fan X, River JN, Zamora M, Al-Hallaq HA, Karczmar GS. Effect of carbogen on tumor oxygenation: combined fluorine-19 and proton MRI measurements. Int J Radiat Oncol Biol Phys 2002;54:1202-9.
130. 19F MRI of perfluorocarbons. Curr Sci 1999;76:753-62.
131. Wang Z, Su M-Y, Nalcioglu O. Applications of dynamic contrast enhanced MRI in oncology: measurement of tumor oxygen tension. Technol Cancer Res Treat 2002;1:29-38.
132. Cooper RA, Carrington BM, Loncasters JA, Todd SM, Davidson SE, Logue JP et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 2000;57:53-9.
133. Lyng H, Vorren AO, Sundfor K, Taksdal I, Lien HH, Kaalhus O et al. Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging. JMRI 2001;14:750-6.
134. Wilson D, Cerniglia G. Localization of tumors and evaluation of their state of oxygenation by phosphorescence imaging. Cancer Res 1992;52:3988-93.
135. Pogue BW, Zhu H, Nwaigwe C, McBride TO, Osterberg UL, Paulsen KD et al. Hemoglobin imaging with hybrid magnetic resonance and near-infrared diffuse tomography. Adv Exp Med Biol 2003;530:215-24.
136. Adamsen TCH, Grierson JR, Krohn KA. A new synthesis of the labeling precursor for [F-18]-fluoromisonidazole. Labelled Comp Radiopharm 2005;48:923-7.
137. Rasey JS, Koh W-J, Grierson JR, Grunbaum Z, Krohn KA. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985-91.
138. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med 2007;37:451-91.
139. Kachur AV, Dolbier WR Jr, Evans SM, Shiue C-Y, Shine GG, Skov KA et al. Synthesis of new hypoxia markers EF1 and [18F]-EF1. Appl Radiat Isot 1999;51:643-50.
140. Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [F-18]EF1. J Nucl Med 2000;41:327-36.
141. Josse O, Labar D, Georges B, Gregoire V, Marchand-Brynaert J. Synthesis of [F-18]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)- acetamide], a marker for PET detection of hypoxia. Biorg Med Chem 2001;9:665-75.
142. Dubois, L., Landuyt, W., Cloetens, L., Bol, A., Bormans, G., Haustermans, K., Labar, D., Nuyts, J., Gregoire, V., and Mortelmans, L. [F-18]EF3 is not superior to [F-18]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. European Journal of Nuclear Medicine and Molecular Imaging, 30: 209-218, 2009.
143. Mahy P, Geets X, Lonneux M, Leveque P, Christian N, De Bast M et al. Determination of tumour hypoxia with [F-18]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. Eur J Nucl Med Mol Imaging 2008;35:1282-9.
144. Dolbier WR, Li AR, Koch CJ, Shiue CY, Kachur AV. [F-18]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 2001;54:73-80.
145. Evans SM, Joiner B, Jenkins WT, Laughlin KM, Lord EM, Koch CJ. Identification of hypoxia in cells and tissues of epigastric 91 rat glioma using Ef5 [2-(2-Nitro-1h-Imidazol-1-Yl)-N-(2,2,3,3,3-Pentafluoropropyl) Acetamide]. Br J Cancer 1995;72:875-82.
146. Koch CJ, Shuman AL, Jenkins WT, Kachur AV, Karp JS, Freifelder R et al. The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake. Int J Radiat Biol 2009;85:1137-47.
147. Komar G, Seppanen M, Eskola O, Lindholm P, Gronroos TJ, Forsback S et al. F-18-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. Nucl Med 2008;49:1944-51.
148. Tewson TJ. Synthesis of [F-18]fluoroetanidazole: A potential new tracer for imaging hypoxia. Nuclear Medicine Biology 1997;24:755-60.
149. Barthel H, Wilson H, Collingridge DR, Brown G, Osman S, Luthra SK et al. In vivo evaluation of [F-18]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer 2004;90:2232-42.
150. Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995;194:795-800.
151. Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE et al. Development of F-18 labeled fluoroerythronitroimidizole as a PET agent for imaging tumor hypoxia. Radiology 1995;194:795-800.
152. Lehtio K, Oikonen V, Nyman S, Gronroos T, Roivainen A, Eskola I, Minn H. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole(IF-18] FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging 2003;30:101-8.
153. Reischl G, Ehrlichmann W, Bieg C, Solbach C, Kumar P, Wiebe LI et al. Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. Radiat Isot 2005;62:897-901.
154. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P et al. Hypoxia-specific tumor imaging with F-18-fluoroazomycin arabinoside. J Nucl Med 2005;46:106-13.
155. Zhang Y, Chu TW, Gao XG, Liu XQ, Yang Z, Guo ZQ et al. Synthesis and preliminary biological evaluation of the Tc-99m labeled nitrobenzoimidazole and nitrotriazole as tumor hypoxia markers. Bioorg Med Chem Lett 2006;16:1831-3.
156. Ballinger JR, Kee JWM, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 1996;37:1023-31.
157. 99mTc]HL-91: correlation with microelectrode measurements. J Nucl Med 2001;42:337-44.
158. Siim BG, Laux WT, Rutland MD, Palmer BN, Wilson WR. Scintigraphic Imaging of the Hypoxia Marker 99mTechnetium-labeled 2,2′-(1,4-Diaminobutane) bis(2-methyl-3-butanone) Dioxime (99mTc-labeled HL-91; Prognox): Noninvasive Detection of Tumor Response to the Antivascular Agent 5,6-Dimethylxanthenone-4- acetic Acid. Cancer Res 2000;60:4582-8.
159. Cook GJR, Houston S, Barrington SF, Fogelman I. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med 1998;39:99-103.
160. Schneider RF, Engelhardt EL, Stobbe CC, Fenning MC, Chapman JD. The synthesis and radiolabelling of novel markers of tissue hypoxia of the iodinated azomycin nucleoside class. Labelled Comp Radiopharm 1997;39:541-57.
161. Moore R, Chapman J, Mercer J, Mannan R, McEwan A, McPhee M. Measurement of PDT-induced hypoxia in Dunning prostate tumors by I-123-iodoazomycin arabinoside. J Nucl Med 1993;34:405-13.
162. Zanzonico P, O'Donoghue J, Chapman JD, Schneider R, Cai S, Larson SD etal. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004;31:117-28.
163. Riedl CC, Brader P, Zanzonico PB, Chun YS, Woo Y, Singh P et al. Imaging hypoxia in orthotopic rat liver tumors with Iodine 124 labeled Iodoazomycin Galactopyranoside PET1. Radiology 2008;248:561-70.
164. Li XF, Sun XR, Ma YY, Suehiro M, Zhang MT, Russell J et al. Detection of hypoxia in microscopic tumors using I-131-labeled iodo-azomycin galactopyranoside (I-131-IAZGP) digital autoradiography. Eur J Nucl Med Mol Imaging 2010;37:339-48.
165. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155-60.
166. Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, Okazawa H. Pathophysiologic correlation between Cu-62-ATSM and F-18-FDG in lung cancer. J Nucl Med 2009;50:1948-53.